First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph(+)) acute lymphoblastic leukemia

The combination of cytotoxic chemotherapy and imatinib has improved the outcome for patients with Philadelphia chromosome–positive (Ph(+)) acute lymphoblastic leukemia (ALL). Dasatinib has significant clinical activity in patients with imatinib resistance. We examined the efficacy and safety of comb...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ravandi, Farhad, O'Brien, Susan, Thomas, Deborah, Faderl, Stefan, Jones, Dan, Garris, Rebecca, Dara, Samuel, Jorgensen, Jeffrey, Kebriaei, Partow, Champlin, Richard, Borthakur, Gautam, Burger, Jan, Ferrajoli, Alessandra, Garcia-Manero, Guillermo, Wierda, William, Cortes, Jorge, Kantarjian, Hagop
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2010
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081177/
https://ncbi.nlm.nih.gov/pubmed/20466853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-12-261586
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados